Table 1.

TTV and HCV detection and loads in the plasma of 25 doubly infected patients at selected times of IFN treatment

Day of treatmentTTVHCV
No. positive/tested (%)1-aLoad1-bNo. positive/tested (%)1-aLoad1-b
Mean ± SERange1-cMean ± SERange1-c
025/25 (100)6.7 ± 0.24.9–9.325/25 (100)6.0 ± 0.24.7–7.4
125/25 (100)6.7 ± 0.24.9–10.322/23 (96)5.2 ± 0.2∗∗ 3.4–6.3
218/18 (100)6.8 ± 0.25.6–9.412/15 (80)5.0 ± 0.3∗∗ 3.7–6.6
312/12 (100)5.9 ± 0.3* 3.1–7.115/17 (88)5.2 ± 0.2** 4.9–6.7
713/14 (93)5.5 ± 0.3** 3.3–7.114/16 (87)5.1 ± 0.3*** 4.8–6.6
1414/19 (74)5.4 ± 0.4** 5.2–8.617/20 (85)4.5 ± 0.2*** 3.3–6.7
306/14 (43)3.8 ± 0.3*** 3.6–7.010/18 (55)4.3 ± 0.3*** 5.3–6.2
907/17 (41)4.1 ± 0.4*** 3.5–7.66/18 (33)4.2 ± 0.4*** 5.3–7.1
  • F1-a Not all samples were available for all patients at all times.

  • F1-b Log10 copies of viral genome per milliliter of plasma. Viral loads below the detection assay sensitivity were arbitrarily scored as 3 log10 for calculation. *, **, ***, significantly different from day 0 at P < 0.05 , P < 0.01 , and P < 0.001 , respectively (Student's t test).

  • F1-c Positive patients only.